Caredex

Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus across the board, led by revenue of $132M (+15.74% vs. expected) and strong testing services demand. GAAP EPS reached $2.07, driven by a $113M gain from the Lab Products divestiture, while non-GAAP EPS of $0.37 outperformed the $0.232 consensus by 59.48%. Following the robust performance and the Naveris acquisition, management raised FY26 revenue guidance to $490M-$500M, well above previous ranges.